98%
921
2 minutes
20
A key challenge in the synthesis of diterpenoid alkaloids lies in identifying strategies that rapidly construct their multiply bridged polycyclic skeletons. Existing approaches to these structurally intricate secondary metabolites are discussed in the context of a "bond-network analysis" of molecular frameworks, which was originally devised by Corey some 40 years ago. The retrosynthesis plans that emerge from a topological analysis of the highly bridged frameworks of the diterpenoid alkaloids are discussed in the context of eight recent syntheses of hetidine and hetisine natural products and their derivatives. This Minireview highlights the extent to which network analyses of the type described here sufficed for designing synthesis plans, as well as areas where they had to be amalgamated with functional group oriented synthetic planning considerations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317470 | PMC |
http://dx.doi.org/10.1002/anie.201909656 | DOI Listing |
Mol Divers
September 2025
Department of Chemistry, College of Science, King Khalid University, P.O. Box 9004, 61413, Abha, Saudi Arabia.
The catalytic asymmetric Mannich reaction is a multicomponent reaction which affords β-amino carbonyl compounds by utilizing an aldehyde, a primary or secondary amine/ammonia, and a ketone. β-amino carbonyl scaffolds are crucial intermediates for the synthesis of naturally occurring bioactive compounds and their derivatives. The synthesized natural compounds exhibit a broad spectrum of biological activities including anti-fungal, anti-cancer, anti-bacterial, anti-HIV, anti-oxidant, and anti-inflammatory activities.
View Article and Find Full Text PDFCancer Med
September 2025
Adem Crosby Cancer Centre, Department of Medical Oncology, Division of Cancer Care Services, Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
Background: The three main chemotherapy regimens for people with unresectable pancreatic cancer include modified FOLFIRINOX (comprising oxaliplatin, irinotecan and fluorouracil, denoted mFFX), gemcitabine with nab-paclitaxel (GnP), and single-agent gemcitabine (GEM). We explored characteristics associated with the type of chemotherapy and variations in survival.
Materials And Methods: Records for people with unresected pancreatic adenocarcinoma between 2018 and 2022 treated with first-line mFFX, GnP or GEM were extracted from the population-based Queensland Oncology Repository.
Phytomedicine
August 2025
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, PR China. Electronic address:
Background: Nonalcoholic fatty liver disease (NAFLD), which is characterized by the accumulation of fat in the liver, has emerged as a leading cause of chronic liver diseases and malignancies. However, there remains a scarcity of approved therapeutic interventions. Brunodelphinine A (BruA) is a diterpenoid alkaloid isolated from Delphinium brunonianum Royle.
View Article and Find Full Text PDFInt Immunopharmacol
September 2025
Teaching and Research Department of Chinese Materia Medica Resources, College of Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China. Electronic address:
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease. The pathogenesis is complex, and the pathological manifestations are mainly articular cartilage and bone injury, synovial destruction, pannus hyperplasia and inflammatory cell infiltration. Polyschistine D (PD) is a natural active product derived from the Chinese herbal medicine Aconitum pendulum Busch.
View Article and Find Full Text PDFJCO Precis Oncol
September 2025
Northwestern University, Chicago, IL.
Purpose: FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GnP) are the most commonly administered first-line (1L) regimens for advanced, nonresectable, pancreatic ductal adenocarcinoma (PDAC). In the absence of biomarkers to predict response, clinical covariates such as age and performance status are often used by clinicians to select optimal treatment regimens. Purity independent subtyping of tumors (PurIST) is a molecular subtyping algorithm that classifies tumors as classical or basal.
View Article and Find Full Text PDF